- Record Total Revenues of $2.09 Billion, Up 36 Percent over First Quarter 2009 -
- Product Sales of $1.79 Billion, Up 24 Percent over First Quarter 2009 -
- First Quarter Non-GAAP EPS of $0.99 per Share, Up 50 Percent over First Quarter 2009 -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended March 31, 2010. Total revenues for the first quarter of 2010 were $2.09 billion, up 36 percent compared to total revenues of $1.53 billion for the first quarter of 2009. Net income for the first quarter of 2010 was $854.9 million, or $0.92 per diluted share, compared to net income for the first quarter of 2009 of $589.1 million, or $0.63 per diluted share. Non-GAAP net income for the first quarter of 2010, which excludes after-tax acquisition-related expenses, restructuring expenses and stock-based compensation expenses, was $914.8 million, or $0.99 per diluted share. Non-GAAP net income for the first quarter of 2009, which excludes after-tax stock-based compensation expenses, was $619.4 million, or $0.66 per diluted share.
Product sales increased 24 percent to $1.79 billion for the first quarter of 2010, compared to $1.45 billion in the first quarter of 2009. This increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth in sales of Truvada® (emtricitabine/tenofovir disoproxil fumarate), as well as the addition of Ranexa® (ranolazine) to Gilead’s commercial portfolio. Product sales were reduced by $29.4 million in the first quarter of 2010 due to the impact of healthcare reform legislation in the United States.
Antiviral product sales increased 19 percent to $1.60 billion in the first quarter of 2010, up from $1.34 billion for the same quarter of 2009. The increase was driven primarily by sales volume growth of Atripla and Truvada.
Sales of Atripla for the treatment of HIV infection increased 36 percent to $692.9 million for the first quarter of 2010, up from $509.9 million in the first quarter of 2009, driven primarily by sales volume growth in the United States and Europe.
Sales of Truvada for the treatment of HIV infection increased 11 percent to $657.8 million for the first quarter of 2010, up from $590.4 million in the first quarter of 2009, driven primarily by sales volume growth in the United States and Europe.
Sales of Viread® (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B increased 13 percent to $180.7 million for the first quarter of 2010, up from $160.6 million in the first quarter of 2009, driven primarily by sales volume growth of Viread in a majority of our markets.
Sales of Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension (PAH) increased 40 percent to $55.5 million for the first quarter of 2010, up from $39.6 million for the first quarter of 2009, driven primarily by sales volume growth in the United States.
Sales of Ranexa for the treatment of chronic angina were $51.2 million for the first quarter of 2010. There were no Ranexa sales in the first quarter of 2009 as Gilead acquired CV Therapeutics, Inc. on April 15, 2009.
Sales of AmBisome® (amphotericin B liposome for injection) for the treatment of severe fungal infections, Hepsera® (adefovir dipivoxil) for the treatment of chronic hepatitis B, Emtriva® (emtricitabine) for the treatment of HIV infection and other products were $150.0 million for the first quarter of 2010 compared to $147.2 million for the first quarter of 2009. Sales of Cayston® (aztreonam for inhalation solution) as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa (P. aeruginosa), included in other products, were $2.9 million during the first quarter of 2010 subsequent to the marketing approval granted by the U.S. Food and Drug Administration (FDA) in February 2010.
Royalty, Contract and Other Revenues
Royalty, contract and other revenues resulting primarily from collaborations with corporate partners were $297.8 million in the first quarter of 2010, up from $82.9 million in the first quarter of 2009. This increase was driven primarily by higher Tamiflu® (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $246.3 million in the first quarter of 2010, compared to Tamiflu royalties of $33.2 million in the first quarter of 2009, resulting from increased sales related to influenza pandemic planning initiatives worldwide.
Research and Development
Research and development (R&D) expenses in the first quarter of 2010 were $218.7 million, compared to $188.8 million for the first quarter of 2009. Non-GAAP R&D expenses for the first quarter of 2010, which exclude restructuring and stock-based compensation expenses, were $196.5 million compared to $171.8 million for the first quarter of 2009, which exclude stock-based compensation expenses. This increase was driven primarily by higher headcount and expenses to support the growth of Gilead’s R&D activities.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses in the first quarter of 2010 were $265.6 million, compared to $204.0 million for the first quarter of 2009. Non-GAAP SG&A expenses for the first quarter of 2010, which exclude restructuring and stock-based compensation expenses, were $229.1 million, compared to $183.1 million for the same quarter in 2009, which exclude stock-based compensation expenses. This increase was driven primarily by higher headcount and expenses to support Gilead’s expanding commercial activities.
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on first quarter 2010 revenues and pre-tax earnings, which includes revenues and expenses generated from outside the United States, was a favorable $1.7 million and $11.0 million, respectively, compared to the first quarter of 2009, and an unfavorable $22.7 million and $17.2 million, respectively, compared to the fourth quarter of 2009.
Cash, Cash Equivalents and Marketable Securities
As of March 31, 2010, Gilead had cash, cash equivalents and marketable securities of $4.62 billion compared to $3.90 billion as of December 31, 2009. Gilead generated $670.6 million of operating cash flow in the first quarter of 2010.
In January, Gilead announced that Per Wold-Olsen had been appointed to its Board of Directors. Mr. Wold-Olsen spent more than 30 years with the global research-based pharmaceutical company Merck & Co., Inc., most recently serving as President of the company’s Human Health Intercontinental Division.
On January 29, Gilead announced that its Board of Directors had authorized the repurchase of up to $1.00 billion of its common stock through January 2011. As of March 31, 2010, Gilead had approximately $837.5 million remaining for share repurchases under this program.
Product and Pipeline Update
In January, Gilead released results from a Phase II clinical trial of its investigational fixed-dose single-tablet (Quad) regimen of elvitegravir, cobicistat (formerly GS 9350) and Truvada for the treatment of HIV infection in antiretroviral treatment-naïve adults. In addition, Gilead released results from a Phase II clinical trial evaluating the safety and efficacy of cobicistat-boosted atazanavir compared to ritonavir-boosted atazanavir, each in combination with Truvada, also in HIV-infected antiretroviral treatment-naïve adults. In February, the full results from both of these studies were presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco.
In February, Gilead announced that the FDA granted marketing approval for Cayston as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with P. aeruginosa.
At 4:30 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss its first quarter 2010 results as well as provide a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-800-591-6944 (U.S.) or 1-617-614-4910 (international) and dial the participant passcode 12529537 to access the call.
A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through April 23, 2010. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 56078089.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the first quarter of 2010 and 2009. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 6.
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to sustain growth in revenues for its antiviral and cardiovascular franchises; unpredictable variability of Tamiflu royalties and the strong relationship between this royalty revenue and global pandemic planning and supply; Gilead’s ability to receive regulatory approvals in a timely manner or at all, for new and current products, including its investigational fixed-dose single-tablet (Quad) regimen of elvitegravir, cobicistat (formerly GS 9350) and Truvada for the treatment of HIV infection and cobicistat as a boosting agent for certain HIV medicines and other antivirals; Gilead’s ability to successfully commercialize any products that may receive regulatory approvals, including Cayston as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with P. aeruginosa; Gilead’s ability to successfully develop its respiratory and cardiovascular franchises; initiating and completing clinical trials may take longer or cost more than expected, including in the clinical study evaluating the Quad and cobicistat as a boosting agent; fluctuations in the foreign exchange rate of the U.S. dollar that may reduce or eliminate the favorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; our ability to consummate the $1.00 billion share repurchase program due to changes in our stock price, corporate or other market conditions; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Annual Report on Form 10-K for the year ended December 31, 2009, subsequent press releases and other publicly filed SEC disclosure documents. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Truvada, Viread, Hepsera, Emtriva, AmBisome, Letairis, Cayston and Ranexa are registered trademarks of Gilead Sciences, Inc.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
|GILEAD SCIENCES, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF INCOME|
|(in thousands, except per share amounts)|
|Three Months Ended|
|Royalty, contract and other revenues||297,790||82,880|
|Costs and expenses:|
|Cost of goods sold||440,430||329,414|
|Research and development||218,664||188,779|
|Selling, general and administrative||265,618||203,951|
|Total costs and expenses||924,712||722,144|
|Income from operations||1,161,141||808,316|
|Interest and other income, net||15,645||4,159|
|Income before provision for income taxes||1,159,831||795,804|
|Provision for income taxes||307,737||209,227|
|Net loss attributable to noncontrolling interest||2,807||2,535|
|Net income attributable to Gilead||$||854,901||$||589,112|
|Net income per share attributable to Gilead common stockholders - basic||$||0.95||$||0.65|
|Net income per share attributable to Gilead common stockholders - diluted||$||0.92||$||0.63|
|Shares used in per share calculation - basic||901,606||909,780|
|Shares used in per share calculation - diluted||928,368||942,479|
|GILEAD SCIENCES, INC.|
|RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION|
|(in thousands, except percentages and per share amounts)|
|Three Months Ended|
|Cost of goods sold reconciliation:|
|GAAP cost of goods sold||$||440,430||$||329,414|
|Acquisition-related amortization of inventory mark-up||(4,978||)||-|
|Acquisition-related amortization of purchased intangibles||(14,984||)||-|
|Stock-based compensation expenses||(2,853||)||(3,254||)|
|Non-GAAP cost of goods sold||$||417,615||$||326,160|
|Product gross margin reconciliation:|
|GAAP product gross margin||75.5||%||77.4||%|
|Acquisition-related amortization of inventory mark-up||0.3||%||-|
|Acquisition-related amortization of purchased intangibles||0.8||%||-|
|Stock-based compensation expenses||0.2||%||0.2||%|
|Non-GAAP product gross margin (1)||76.7||%||77.6||%|
|Research and development expenses reconciliation:|
|GAAP research and development expenses||$||218,664||$||188,779|
|Stock-based compensation expenses||(20,069||)||(16,955||)|
|Non-GAAP research and development expenses||$||196,495||$||171,824|
|Selling, general and administrative expenses reconciliation:|
|GAAP selling, general and administrative expenses||$||265,618||$||203,951|
|Stock-based compensation expenses||(23,919||)||(20,836||)|
|Non-GAAP selling, general and administrative expenses||$||229,115||$||183,115|
|Operating margin reconciliation:|
|GAAP operating margin||55.7||%||52.8||%|
|Acquisition-related amortization of inventory mark-up||0.2||%||-|
|Acquisition-related amortization of purchased intangibles||0.7||%||-|
|Stock-based compensation expenses||2.2||%||2.7||%|
|Non-GAAP operating margin (1)||59.6||%||55.5||%|
|Net income attributable to Gilead reconciliation:|
|GAAP net income attributable to Gilead||$||854,901||$||589,112|
|Acquisition-related amortization of inventory mark-up||3,657||-|
|Acquisition-related amortization of purchased intangibles||11,008||-|
|Stock-based compensation expenses||34,413||30,288|
|Non-GAAP net income attributable to Gilead||$||914,767||$||619,400|
|Diluted earnings per share reconciliation:|
|GAAP diluted earnings per share||$||0.92||$||0.63|
|Acquisition-related amortization of inventory mark-up||0.00||-|
|Acquisition-related amortization of purchased intangibles||0.01||-|
|Stock-based compensation expenses||0.04||0.03|
|Non-GAAP diluted earnings per share (1)||$||0.99||$||0.66|
|Shares used in per share calculation (diluted) reconciliation:|
|GAAP shares used in per share calculation (diluted)||928,368||942,479|
|Share impact of current stock-based compensation guidance||(703||)||799|
|Non-GAAP shares used in per share calculation (diluted)||927,665||943,278|
|Non-GAAP adjustment summary:|
|Cost of goods sold adjustments||$||22,815||$||3,254|
|Research and development expenses adjustments||22,169||16,955|
|Selling, general and administrative expenses adjustments||36,503||20,836|
|Total non-GAAP adjustments before tax||81,487||41,045|
Income tax effect
|Total non-GAAP adjustments after tax||$||59,866||$||30,288|
|(1) Amounts may not sum due to rounding|
|GILEAD SCIENCES, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash, cash equivalents and marketable securities||$||4,619,915||$||3,904,846|
|Accounts receivable, net||1,491,332||1,389,534|
|Property, plant and equipment, net||695,601||699,970|
|Total liabilities and stockholders’ equity||$||10,695,998||$||9,698,559|
|(1) Derived from audited consolidated financial statements at that date.|
|GILEAD SCIENCES, INC.|
|PRODUCT SALES SUMMARY|
|Three Months Ended|
|Atripla – U.S.||$||455,901||$||374,132|
|Atripla – Europe||217,548||124,779|
|Atripla – Other International||19,423||10,972|
|Truvada – U.S.||326,817||280,997|
|Truvada – Europe||297,528||278,440|
|Truvada – Other International||33,454||30,916|
|Viread – U.S.||78,007||69,589|
|Viread – Europe||73,143||65,331|
|Viread – Other International||29,536||25,685|
|Hepsera – U.S.||21,565||25,652|
|Hepsera – Europe||33,375||38,917|
|Hepsera – Other International||3,184||8,145|
|Emtriva – U.S.||4,244||3,630|
|Emtriva – Europe||1,875||2,354|
|Emtriva – Other International||1,037||1,250|
|Total Antiviral products – U.S.||886,534||754,000|
|Total Antiviral products – Europe||623,469||509,821|
|Total Antiviral products – Other International||86,634||76,968|
|Total product sales||$||1,788,063||$||1,447,580|
Gilead Sciences, Inc.
Robin Washington, 650-522-5688
Susan Hubbard, 650-522-5715
Amy Flood, 650-522-5643
KEYWORDS: United States Europe North America California
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Pharmaceutical